Koers American Oriental Bioengineering, Inc. Other OTC
Aandelen
AOBI
US0287315032
Farmaceutische producten
Omzet 2011 | 213 mln. 199 mln. | Omzet 2012 | 145 mln. 136 mln. | Marktkapitalisatie | 13,35 mln. 12,47 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2011 | -67 mln. -62,6 mln. | Nettowinst (verlies) 2012 | -59 mln. -55,13 mln. | EV/omzet 2011 | 0,5 x |
Nettoschuld 2011 | 63,31 mln. 59,15 mln. | Nettoschuld 2012 | 49,49 mln. 46,24 mln. | EV/omzet 2012 | 0,43 x |
K/w-verhouding 2011 |
-0,62
x | K/w-verhouding 2012 |
-0,22
x | Werknemers | - |
Dividendrendement 2011 * |
-
| Dividendrendement 2012 |
-
| Vrij verhandelbaar | 5,48% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yan Chun Li
FOU | Founder | 55 | - |
Shujun Liu
CEO | Chief Executive Officer | 71 | 30-11-70 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shujun Liu
CEO | Chief Executive Officer | 71 | 30-11-70 |
Yan Chun Li
FOU | Founder | 55 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+50,70% | 791 mld. | |
+41,96% | 630 mld. | |
-7,15% | 350 mld. | |
+18,77% | 328 mld. | |
+8,79% | 298 mld. | |
+18,02% | 246 mld. | |
+1,27% | 225 mld. | |
+11,95% | 218 mld. | |
+3,68% | 160 mld. |